WT5
MCID: WLM018
MIFTS: 62

Wilms Tumor 5 (WT5)

Categories: Blood diseases, Cancer diseases, Fetal diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 5

MalaCards integrated aliases for Wilms Tumor 5:

Name: Wilms Tumor 5 56 52
Wilms Tumor 25 54 6 42 39
Wilms Tumor and Radial Bilateral Aplasia 52 29 6 71
Wilms Tumor Susceptibility-5 56 29 13
Wt5 56 52 73
Nephroblastoma 25 71
Hereditary Susceptibility to Wilms Tumor 5 73
Bilateral Radial Aplasia with Wilms Tumor 52
Kidney, Adenomyosarcoma, Embryonal 25
Kidney, Carcinosarcoma, Embryonal 25
Wilms Tumor, Susceptibility to 56
Kidney, Embryonal Mixed Tumor 25
Embryonal Adenosarcoma 25
Renal Cancer, Wilms 25
Wilms Tumor, Type 5 39
Wilms Tumor ; Wtsl 56
Embryonal Nephroma 25
Kidney Wilms Tumor 25
Renal Adenosarcoma 25
Renal Wilms Tumor 25
Kidney, Embryoma 25
Wilms' Tumor 25
Tumor, Wilms 25
Nephroma 25
Wtsl 56

Characteristics:

OMIM:

56
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
most cases are sporadic
tumor suppressor gene


HPO:

31

Classifications:



External Ids:

OMIM 56 601583
OMIM Phenotypic Series 56 PS194070
MedGen 41 C1832099
UMLS 71 C0027708 C1832099

Summaries for Wilms Tumor 5

Genetics Home Reference : 25 Wilms tumor is a form of kidney cancer that primarily develops in children. Nearly all cases of Wilms tumor are diagnosed before the age of 10, with two-thirds being found before age 5. Wilms tumor is often first noticed because of abdominal swelling or a mass in the kidney that can be felt upon physical examination. Some affected children have abdominal pain, fever, a low number of red blood cells (anemia), blood in the urine (hematuria), or high blood pressure (hypertension). Additional signs of Wilms tumor can include loss of appetite, weight loss, nausea, vomiting, and tiredness (lethargy). Wilms tumor can develop in one or both kidneys. About 5 to 10 percent of affected individuals develop multiple tumors in one or both kidneys. Wilms tumor may spread from the kidneys to other parts of the body (metastasize). In rare cases, Wilms tumor does not involve the kidneys and occurs instead in the genital tract, bladder, abdomen, chest, or lower back. It is unclear how Wilms tumor develops in these tissues. With proper treatment, children with Wilms tumor have a 90 percent survival rate. However, the risk that the cancer will come back (recur) is between 15 and 50 percent, depending on traits of the original tumor. Tumors usually recur in the first 2 years following treatment and develop in the kidneys or other tissues, such as the lungs. Individuals who have had Wilms tumor may experience related health problems or late effects of their treatment in adulthood, such as decreased kidney function, heart disease, and development of additional cancers.

MalaCards based summary : Wilms Tumor 5, also known as wilms tumor, is related to adult mesoblastic nephroma and wilms tumor predisposition, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 5 is POU6F2 (POU Class 6 Homeobox 2), and among its related pathways/superpathways are Proteoglycans in cancer and Glioblastoma Multiforme. The drugs Miconazole and Itraconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, myeloid and t cells, and related phenotypes are nephroblastoma and embryo

MedlinePlus : 42 Wilms tumor is a rare type of kidney cancer. It causes a tumor on one or both kidneys. It usually affects children, but can happen in adults. Having certain genetic conditions or birth defects can increase the risk of getting it. Children that are at risk should be screened for Wilms tumor every three months until they turn eight. Symptoms include a lump in the abdomen, blood in the urine, and a fever for no reason. Tests that examine the kidney and blood are used to find the tumor. Doctors usually diagnose and remove the tumor in surgery. Other treatments include chemotherapy and radiation and biologic therapies. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 73 Hereditary susceptibility to Wilms tumor 5: Pediatric malignancy of kidney and one of the most common solid cancers in childhood.

More information from OMIM: 601583 PS194070

Related Diseases for Wilms Tumor 5

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 828)
# Related Disease Score Top Affiliating Genes
1 adult mesoblastic nephroma 33.0 WT1 PAX8
2 wilms tumor predisposition 33.0 WT1 IGF2 H19 GPC3 CDKN1C
3 simpson-golabi-behmel syndrome 32.7 GPC3 CTNNB1
4 aniridia 1 32.5 WT1 PAX6 PAX2
5 ovarian wilms' cancer 31.2 WT1 PAX8 GPC3
6 benign mesothelioma 30.5 WT1 PAX8
7 wilms tumor 1 30.5 WTAP WT1 POU6F2 PAX8 PAX6 PAX2
8 teratoma 30.4 H19 GPC3 CTNNB1
9 adrenocortical carcinoma, hereditary 30.4 IGF2 H19 CTNNB1
10 hemihyperplasia, isolated 30.2 WT1 IGF2 H19 CDKN1C
11 silver-russell syndrome 30.2 IGF2 H19 CDKN1C
12 adrenal cortical carcinoma 30.1 IGF2 CTNNB1 CDKN1C
13 focal segmental glomerulosclerosis 30.1 WT1 PAX2 CTNNB1 CDKN1C
14 embryonal sarcoma 30.1 GPC3 CTNNB1
15 sarcoma, synovial 29.8 WT1 IGF2 CTNNB1
16 umbilical hernia 29.8 IGF2 H19 CDKN1C
17 carcinosarcoma 29.8 WT1 PAX8 CTNNB1
18 pax6-related aniridia 29.7 WT1 PAX6 IGF2 H19 GPC3
19 rhabdomyosarcoma 29.6 SLC22A18 IGF2 H19 CDKN1C CCN3 CCN1
20 female reproductive endometrioid cancer 29.5 WT1 PAX8 CTNNB1
21 renal cell carcinoma, papillary, 1 29.4 WT1 PAX8 PAX2 CTNNB1
22 ovary adenocarcinoma 29.4 WT1 PAX8 CTNNB1
23 renal cell carcinoma, nonpapillary 29.3 WTAP WT1 PAX8 PAX2 H19 CCN3
24 renal hypodysplasia/aplasia 1 29.2 WT1 PAX8 PAX2 IGF2
25 clear cell renal cell carcinoma 29.0 WT1 PAX8 PAX2 CTNNB1
26 hepatoblastoma 28.7 SLC22A18 IGF2 H19 GPC3 CTNNB1 CDKN1C
27 beckwith-wiedemann syndrome 28.7 WT1 SLC22A18 NAP1L4 IGF2 H19 GPC3
28 endometrial cancer 28.2 WT1 PAX8 IGF2 H19 CTNNB1 CCN1
29 cervical wilms' tumor 12.7
30 global developmental delay, lung cysts, overgrowth, and wilms tumor 12.6
31 wilms tumor 4 12.5
32 epithelial predominant wilms' tumor 12.5
33 stromal predominant kidney wilms' tumor 12.5
34 renal wilms' tumor 12.5
35 wilms tumor 3 12.5
36 blastema predominant kidney wilms' tumor 12.5
37 familial wilms tumor 2 12.4
38 cellular congenital mesoblastic nephroma 12.4
39 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.4
40 mixed cell type kidney wilms' tumor 12.3
41 metachronous kidney wilms' tumor 12.3
42 classic congenital mesoblastic nephroma 12.3
43 frasier syndrome 11.9
44 mulibrey nanism 11.7
45 hyperparathyroidism 2 with jaw tumors 11.7
46 mosaic variegated aneuploidy syndrome 3 11.7
47 mosaic variegated aneuploidy syndrome 11.7
48 li-fraumeni syndrome 11.6
49 li-fraumeni syndrome 2 11.6
50 bohring-opitz syndrome 11.6

Graphical network of the top 20 diseases related to Wilms Tumor 5:



Diseases related to Wilms Tumor 5

Symptoms & Phenotypes for Wilms Tumor 5

Human phenotypes related to Wilms Tumor 5:

31
# Description HPO Frequency HPO Source Accession
1 nephroblastoma 31 HP:0002667

Symptoms via clinical synopsis from OMIM:

56
Genitourinary Kidneys:
nephroblastoma (wilms tumor)

Neoplasia:
nephroblastoma (wilms tumor)

Clinical features from OMIM:

601583

UMLS symptoms related to Wilms Tumor 5:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 5:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.85 CCN1 CTNNB1 FZD6 GPC3 IGF2 PAX2
2 hearing/vestibular/ear MP:0005377 9.43 CCN5 CTNNB1 FZD6 PAX2 PAX6 PAX8
3 renal/urinary system MP:0005367 9.23 CCN3 CTNNB1 GPC3 IGF2 PAX2 PAX6

Drugs & Therapeutics for Wilms Tumor 5

Drugs for Wilms Tumor 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 247)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
3
Epirubicin Approved Phase 4 56420-45-2 41867
4
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
5
Dactinomycin Approved, Investigational Phase 4 50-76-0 2019 457193
6
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
7
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
8
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 5280972 54715139
9
Pirarubicin Investigational Phase 4 72496-41-4
10 Hormone Antagonists Phase 4
11 Antifungal Agents Phase 4
12 Cytochrome P-450 CYP3A Inhibitors Phase 4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Steroid Synthesis Inhibitors Phase 4
15
Hydroxyitraconazole Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Antimitotic Agents Phase 4
18
Liposomal doxorubicin Phase 4 31703
19
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
20
Etoposide Approved Phase 3 33419-42-0 36462
21
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
22
Sulfamethoxazole Approved Phase 3 723-46-6 5329
23
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
24
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
25
Acyclovir Approved Phase 3 59277-89-3 2022
26
Ribavirin Approved Phase 3 36791-04-5 37542
27
Palivizumab Approved, Investigational Phase 3 188039-54-5
28
Captopril Approved Phase 3 62571-86-2 44093
29
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
30
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
31
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
32
Daunorubicin Approved Phase 3 20830-81-3 30323
33
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
34
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
36
Histamine Approved, Investigational Phase 3 51-45-6 774
37
Cyproheptadine Approved Phase 3 129-03-3 2913
38
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
39
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
40 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
41 Topoisomerase Inhibitors Phase 3
42 Immunosuppressive Agents Phase 3
43 Immunologic Factors Phase 3
44 Etoposide phosphate Phase 3
45 Antiviral Agents Phase 3
46 Liver Extracts Phase 3
47 Protein Kinase Inhibitors Phase 3
48 Antibodies, Monoclonal Phase 3
49 Antibodies Phase 3
50 Immunoglobulins Phase 3

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer Unknown status NCT00491946 Phase 4 Actinomycin-D;Vincristine
2 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
3 A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma. Not yet recruiting NCT03892330 Phase 4 Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
4 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
5 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
6 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
7 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
8 Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
9 NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
10 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
11 Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR Completed NCT00179829 Phase 2, Phase 3
12 National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
13 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
14 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
15 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
16 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
17 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
18 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
19 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
20 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
21 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
22 A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD Completed NCT01371981 Phase 3 Asparaginase;Bortezomib;Cytarabine;Daunorubicin Hydrochloride;Etoposide;Mitoxantrone Hydrochloride;Sorafenib Tosylate
23 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor Active, not recruiting NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
25 Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) Not yet recruiting NCT03669783 Phase 3 treatment Vincristin;treatment Actinomycin-D;treatment Doxorubicin;treatment Carboplatin;Etoposide
26 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial Unknown status NCT00965224 Phase 2
28 Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
29 Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study Unknown status NCT01291420 Phase 1, Phase 2
30 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
31 A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy Unknown status NCT02624388 Phase 2 Genistein;Placebo
32 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
33 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
34 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
35 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
36 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
37 Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
38 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
39 A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation Completed NCT00405327 Phase 2
40 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
41 A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer Completed NCT00365768 Phase 2 Glutamine
42 Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia Completed NCT01095926 Phase 2 doxorubicin
43 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
44 Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
45 Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
46 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
47 Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
48 Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation Completed NCT00309907 Phase 2 methylprednisolone
49 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
50 Phase I/II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT00052520 Phase 1, Phase 2

Search NIH Clinical Center for Wilms Tumor 5

Genetic Tests for Wilms Tumor 5

Genetic tests related to Wilms Tumor 5:

# Genetic test Affiliating Genes
1 Wilms Tumor and Radial Bilateral Aplasia 29 POU6F2
2 Wilms Tumor Susceptibility-5 29

Anatomical Context for Wilms Tumor 5

MalaCards organs/tissues related to Wilms Tumor 5:

40
Kidney, Myeloid, T Cells, Lung, Bone, Bone Marrow, Breast

Publications for Wilms Tumor 5

Articles related to Wilms Tumor 5:

(show top 50) (show all 7163)
# Title Authors PMID Year
1
Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. 61 56 6
15459955 2004
2
Refinement within single yeast artificial chromosome clones of a minimal region commonly deleted on the short arm of chromosome 7 in Wilms tumours. 56 6
11284034 2001
3
Localization of a novel t(1;7) translocation associated with Wilms' tumor predisposition and skeletal abnormalities. 61 56
8946193 1996
4
Germline and somatic abnormalities of chromosome 7 in Wilms' tumor. 61 56
7954327 1994
5
Update on Wilms tumor. 61 42
30270120 2019
6
The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour. 56
12618763 2003
7
Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour. 56
9690521 1998
8
Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors. 56
8938443 1996
9
The genetic changes of Wilms tumour. 42
30705419 2019
10
The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. 42
30310143 2018
11
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. 54 61
20166202 2010
12
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. 54 61
20435628 2010
13
Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. 54 61
20332316 2010
14
Wilms tumor suppressor 1 (WT1) and early growth response 1 (EGR1) are regulators of STIM1 expression. 54 61
20123987 2010
15
The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells. 54 61
20204298 2010
16
Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. 54 61
20423567 2010
17
Conditionally immortalized human podocyte cell lines established from urine. 54 61
19955187 2010
18
Integrative genomic analyses on interferon-lambdas and their roles in cancer prediction. 54 61
20043142 2010
19
Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. 54 61
19348510 2010
20
Peptide vaccines for patients with acute myeloid leukemia. 54 61
19803762 2009
21
High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor. 54 61
19749460 2009
22
Myocardial adenomatoid tumor in eight cattle: evidence for mesothelial origin of bovine myocardial epithelial inclusions. 54 61
19430001 2009
23
Nuclear degradation of Wilms tumor 1-associating protein and survivin splice variant switching underlie IGF-1-mediated survival. 54 61
19605357 2009
24
WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? 54 61
19530245 2009
25
Expression of stem cell markers in the human fetal kidney. 54 61
19696931 2009
26
Paratesticular müllerian-type papillary serous tumor in a child. 54 61
19348511 2009
27
A novel WT1 mutation in a 46,XY boy with congenital bilateral cryptorchidism, nystagmus and Wilms tumor. 54 61
19048299 2009
28
Calcifying nested stromal-epithelial tumors of the liver: a clinicopathologic, immunohistochemical, and molecular genetic study of 9 cases with a long-term follow-up. 54 61
19363442 2009
29
Serous adenocarcinoma of the retroperitoneum, as a type of multifocal müllerian carcinoma. 54 61
19593619 2009
30
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. 54 61
19463768 2009
31
The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. 54 61
19416806 2009
32
Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2. 54 61
19342968 2009
33
TTF-1 expression in nephroblastoma. 54 61
19011567 2009
34
Radiosensitization by inhibiting STAT1 in renal cell carcinoma. 54 61
19100922 2009
35
Wilms' tumor gene 1 (WT1) in endometrial carcinoma. 54 61
18929401 2008
36
Regulation of CRABP-II expression by MycN in Wilms tumor. 54 61
18955045 2008
37
Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. 54 61
19047088 2008
38
WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis. 54 61
19048125 2008
39
Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2. 54 61
18922980 2008
40
Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. 54 61
18724243 2008
41
Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. 54 61
18543005 2008
42
Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. 54 61
18618575 2008
43
Wilms' tumor protein (-KTS) modulates renin gene transcription. 54 61
18496514 2008
44
Brain-derived neurotrophic factor and obesity in the WAGR syndrome. 54 61
18753648 2008
45
The Wilms' tumor suppressor WT1 inhibits malignant progression of neoplastigenic mammary epithelial cells. 54 61
18751389 2008
46
TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. 54 61
18535006 2008
47
Ectopic Pax2 expression in chick ventral optic cup phenocopies loss of Pax2 expression. 54 61
18485342 2008
48
Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. 54 61
18311776 2008
49
Expression of multidrug resistance-related protein (MRP-1), lung resistance-related protein (LRP) and topoisomerase-II (TOPO-II) in Wilms' tumor: immunohistochemical study using TMA methodology. 54 61
18795074 2008
50
In silico regulatory analysis for exploring human disease progression. 54 61
18564415 2008

Variations for Wilms Tumor 5

ClinVar genetic disease variations for Wilms Tumor 5:

6 (show top 50) (show all 100) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MED12 NM_005120.3(MED12):c.131G>A (p.Gly44Asp)SNV other 92220 rs199469672 X:70339254-70339254 X:71119404-71119404
2 CTNNB1 NM_001904.4(CTNNB1):c.770C>T (p.Thr257Ile)SNV other 438758 rs1553630452 3:41267186-41267186 3:41225695-41225695
3 TET2 NM_001127208.2(TET2):c.4456T>C (p.Ser1486Pro)SNV other 438791 rs1553918194 4:106193994-106193994 4:105272837-105272837
4 FZD6 NM_003506.4(FZD6):c.346C>T (p.Arg116Ter)SNV Pathogenic 438765 rs769116796 8:104330986-104330986 8:103318758-103318758
5 CTNNB1 NM_001904.4(CTNNB1):c.133_135del (p.Ser45del)deletion Pathogenic 17576 rs587776850 3:41266136-41266138 3:41224643-41224645
6 POU6F2 NM_007252.4(POU6F2):c.573G>T (p.Gln191His)SNV Pathogenic 1871 rs121918261 7:39379302-39379302 7:39339703-39339703
7 POU6F2 POU6F2, C-G, EXON 1C, 5-PRIME UTRSNV Pathogenic 1872
8 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe)SNV Pathogenic/Likely pathogenic 17588 rs121913409 3:41266137-41266137 3:41224646-41224646
9 VHL NM_000551.3(VHL):c.241C>T (p.Pro81Ser)SNV Conflicting interpretations of pathogenicity 2233 rs104893829 3:10183772-10183772 3:10142088-10142088
10 WT1 NM_024426.6(WT1):c.123G>C (p.Pro41=)SNV Conflicting interpretations of pathogenicity 193453 rs555140661 11:32456784-32456784 11:32435238-32435238
11 WT1 NM_024426.6(WT1):c.375C>T (p.Gly125=)SNV Conflicting interpretations of pathogenicity 241481 rs776209354 11:32456532-32456532 11:32434986-32434986
12 WT1 NM_024426.6(WT1):c.381C>G (p.Pro127=)SNV Conflicting interpretations of pathogenicity 261711 rs771681406 11:32456526-32456526 11:32434980-32434980
13 WT1 NM_024426.6(WT1):c.390A>G (p.Pro130=)SNV Conflicting interpretations of pathogenicity 304424 rs886048228 11:32456517-32456517 11:32434971-32434971
14 WT1 NM_024426.6(WT1):c.1200C>T (p.Tyr400=)SNV Conflicting interpretations of pathogenicity 304418 rs886048227 11:32417867-32417867 11:32396321-32396321
15 WT1 NM_024426.6(WT1):c.-106C>TSNV Conflicting interpretations of pathogenicity 304438 rs867975105 11:32457012-32457012 11:32435466-32435466
16 WT1 NM_024426.6(WT1):c.-140C>TSNV Uncertain significance 304442 rs886048244 11:32457046-32457046 11:32435500-32435500
17 WT1 NM_024426.6(WT1):c.1198T>C (p.Tyr400His)SNV Uncertain significance 304419 rs746353651 11:32417869-32417869 11:32396323-32396323
18 WT1 NM_024426.6(WT1):c.-90T>CSNV Uncertain significance 304435 rs886048238 11:32456996-32456996 11:32435450-32435450
19 WT1 NM_024426.6(WT1):c.*768A>CSNV Uncertain significance 304392 rs886048215 11:32409836-32409836 11:32388290-32388290
20 WT1 NM_024426.6(WT1):c.*666A>GSNV Uncertain significance 304396 rs374306749 11:32409938-32409938 11:32388392-32388392
21 WT1 NM_024426.6(WT1):c.*611C>TSNV Uncertain significance 304398 rs886048220 11:32409993-32409993 11:32388447-32388447
22 WT1 NM_024426.6(WT1):c.1017-15T>CSNV Uncertain significance 304420 rs374441355 11:32421605-32421605 11:32400059-32400059
23 WT1 NM_024426.6(WT1):c.695G>C (p.Ser232Thr)SNV Uncertain significance 304422 rs761913397 11:32450132-32450132 11:32428586-32428586
24 WT1 NM_024426.6(WT1):c.587G>A (p.Gly196Asp)SNV Uncertain significance 304423 rs753112302 11:32456320-32456320 11:32434774-32434774
25 WT1 NM_024426.6(WT1):c.347C>T (p.Pro116Leu)SNV Uncertain significance 304425 rs886048229 11:32456560-32456560 11:32435014-32435014
26 WT1 NM_024426.6(WT1):c.285C>T (p.Gly95=)SNV Uncertain significance 304426 rs886048230 11:32456622-32456622 11:32435076-32435076
27 WT1 NM_024426.6(WT1):c.-31G>TSNV Uncertain significance 304431 rs886048234 11:32456937-32456937 11:32435391-32435391
28 MSH2 NM_000251.2(MSH2):c.2321T>C (p.Ile774Thr)SNV Uncertain significance 408514 rs878853811 2:47705521-47705521 2:47478382-47478382
29 WT1 NM_024426.6(WT1):c.411_413GCC[5] (p.Pro141dup)short repeat Uncertain significance 406690 rs760304811 11:32456484-32456485 11:32434938-32434939
30 WT1 NM_024426.6(WT1):c.*239G>ASNV Uncertain significance 304411 rs886048226 11:32410365-32410365 11:32388819-32388819
31 WT1 NM_024426.6(WT1):c.*1167T>GSNV Uncertain significance 304373 rs771770230 11:32409437-32409437 11:32387891-32387891
32 WT1 NM_024426.6(WT1):c.*513C>TSNV Uncertain significance 304403 rs575602262 11:32410091-32410091 11:32388545-32388545
33 WT1 NM_024426.6(WT1):c.247G>T (p.Ala83Ser)SNV Uncertain significance 304427 rs886048231 11:32456660-32456660 11:32435114-32435114
34 WT1 NM_024426.6(WT1):c.174C>G (p.Leu58=)SNV Uncertain significance 304428 rs886048232 11:32456733-32456733 11:32435187-32435187
35 WT1 NM_024426.6(WT1):c.136G>T (p.Ala46Ser)SNV Uncertain significance 304430 rs886048233 11:32456771-32456771 11:32435225-32435225
36 WT1 NM_024426.6(WT1):c.-76T>CSNV Uncertain significance 304432 rs886048235 11:32456982-32456982 11:32435436-32435436
37 WT1 NM_024426.6(WT1):c.-86T>CSNV Uncertain significance 304434 rs886048237 11:32456992-32456992 11:32435446-32435446
38 WT1 NM_024426.6(WT1):c.-94G>CSNV Uncertain significance 304436 rs886048239 11:32457000-32457000 11:32435454-32435454
39 WT1 NM_024426.6(WT1):c.*1225T>CSNV Uncertain significance 304371 rs886048210 11:32409379-32409379 11:32387833-32387833
40 WT1 NM_024426.6(WT1):c.*1021_*1022GT[15]short repeat Uncertain significance 304379 rs58549495 11:32409550-32409553 11:32388004-32388007
41 WT1 NM_024426.6(WT1):c.*1021_*1022GT[19]short repeat Uncertain significance 304377 rs58549495 11:32409549-32409550 11:32388003-32388004
42 WT1 NM_024426.6(WT1):c.*741G>TSNV Uncertain significance 304393 rs886048216 11:32409863-32409863 11:32388317-32388317
43 WT1 NM_024426.6(WT1):c.*534C>TSNV Uncertain significance 304402 rs868546165 11:32410070-32410070 11:32388524-32388524
44 WT1 NM_024426.6(WT1):c.*366C>ASNV Uncertain significance 304406 rs886048223 11:32410238-32410238 11:32388692-32388692
45 WT1 NM_024426.6(WT1):c.*354G>TSNV Uncertain significance 304407 rs886048224 11:32410250-32410250 11:32388704-32388704
46 WT1 NM_024426.6(WT1):c.*841C>ASNV Uncertain significance 304388 rs886048213 11:32409763-32409763 11:32388217-32388217
47 WT1 NM_024426.6(WT1):c.*269G>TSNV Uncertain significance 304409 rs886048225 11:32410335-32410335 11:32388789-32388789
48 WT1 NM_024426.6(WT1):c.*685G>TSNV Uncertain significance 304395 rs886048218 11:32409919-32409919 11:32388373-32388373
49 WT1 NM_024426.6(WT1):c.*614A>CSNV Uncertain significance 304397 rs886048219 11:32409990-32409990 11:32388444-32388444
50 WT1 NM_024426.6(WT1):c.*110C>TSNV Uncertain significance 304415 rs757474299 11:32410494-32410494 11:32388948-32388948

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 5:

73
# Symbol AA change Variation ID SNP ID
1 POU6F2 p.Gln192His VAR_022419

Expression for Wilms Tumor 5

Search GEO for disease gene expression data for Wilms Tumor 5.

Pathways for Wilms Tumor 5

Pathways related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.57 IGF2 GPC3 FZD6 CTNNB1
2 11.48 IGF2 FZD6 CTNNB1
3 10.79 WT1 PAX2 CTNNB1 CDKN1C
4 10.36 PAX8 PAX2

GO Terms for Wilms Tumor 5

Biological processes related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.16 WTAP POU6F2 PAX8 PAX6 PAX2 IGF2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 WT1 PRDM2 PAX8 PAX6 PAX2 IGF2
3 positive regulation of transcription, DNA-templated GO:0045893 9.87 WT1 PRDM2 PAX8 PAX6 PAX2 CTNNB1
4 negative regulation of cell death GO:0060548 9.83 CCN5 CCN3 CCN1
5 negative regulation of epithelial cell proliferation GO:0050680 9.82 PAX6 GPC3 CDKN1C
6 inner ear morphogenesis GO:0042472 9.8 PAX8 PAX2 FZD6
7 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.67 PAX8 PAX2
8 male genitalia development GO:0030539 9.67 WT1 CTNNB1
9 anterior/posterior axis specification GO:0009948 9.66 GPC3 CTNNB1
10 urogenital system development GO:0001655 9.66 PAX8 PAX2
11 mesonephros development GO:0001823 9.65 PAX8 PAX2
12 mesenchymal to epithelial transition GO:0060231 9.65 WT1 PAX2
13 metanephric mesenchyme development GO:0072075 9.64 WT1 PAX2
14 cellular response to gonadotropin stimulus GO:0071371 9.63 WT1 PAX8
15 dorsal/ventral axis specification GO:0009950 9.63 PAX6 CTNNB1
16 positive regulation of core promoter binding GO:1904798 9.61 PAX6 CTNNB1
17 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.61 PAX8 PAX2
18 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.6 PAX8 PAX2
19 embryonic placenta morphogenesis GO:0060669 9.59 IGF2 CDKN1C
20 pronephros development GO:0048793 9.58 PAX8 PAX2
21 metanephric S-shaped body morphogenesis GO:0072284 9.58 WT1 PAX8
22 positive regulation of epithelial cell differentiation GO:0030858 9.57 PAX6 CTNNB1
23 metanephric nephron tubule formation GO:0072289 9.56 PAX8 PAX2
24 camera-type eye development GO:0043010 9.56 WT1 PAX6 PAX2 CDKN1C
25 metanephric distal convoluted tubule development GO:0072221 9.55 PAX8 PAX2
26 kidney development GO:0001822 9.55 WT1 PAX8 GPC3 CTNNB1 CDKN1C
27 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.54 PAX8 PAX2
28 cell fate determination GO:0001709 9.54 PAX6 PAX2 CTNNB1
29 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.52 PAX8 PAX2
30 positive regulation of metanephric DCT cell differentiation GO:2000594 9.49 PAX8 PAX2
31 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.48 PAX8 PAX2
32 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.46 PAX8 PAX2
33 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.43 PAX8 PAX2
34 pronephric field specification GO:0039003 9.4 PAX8 PAX2
35 metanephric epithelium development GO:0072207 9.13 WT1 PAX8 PAX2
36 branching involved in ureteric bud morphogenesis GO:0001658 9.02 WT1 PAX8 PAX2 GPC3 CTNNB1

Molecular functions related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.8 WT1 PRDM2 POU6F2 PAX8 PAX6 PAX2
2 DNA-binding transcription factor activity GO:0003700 9.7 WT1 PRDM2 POU6F2 PAX8 PAX6 PAX2
3 transcription regulatory region DNA binding GO:0044212 9.56 WT1 PAX8 PAX6 PAX2
4 integrin binding GO:0005178 9.26 IGF2 CCN5 CCN3 CCN1
5 insulin-like growth factor binding GO:0005520 8.8 CCN5 CCN3 CCN1

Sources for Wilms Tumor 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....